← Back to all trials
Active Not Recruiting
NCT03954236
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Conditions: Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Sex: All
Ages: 12 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 24
Sponsor: Memorial Sloan Kettering Cancer Center
Location: Memorial Sloan Kettering Cancer Center New York New York
Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
Eligibility Criteria
Inclusion Criteria:
* Patients (≥ 12 years)
* History of allogeneic hematopoietic stem cell transplantation
* BSA of at least 2% of clinically or histologically confirmed non-sclerotic cutaneous chronic graft-versus-host disease (diagnosed and BSA calculated in accordance with the National Institutes of Health Chronic Graft-versus-Host Disease Consensus for Clinical Trials: I. The 2014 Diagnosis and Staging Working Group Report)
* Patients age ≥ 18 years must provide written informed consent; or patients age ≥12 years and \
Source: ClinicalTrials.gov (NCT03954236). StuddyBuddy aggregates publicly available trial information.
